Your browser is no longer supported. Please, upgrade your browser.
Settings
IMMU Immunomedics, Inc. daily Stock Chart
IMMU [NASD]
Immunomedics, Inc.
Index- P/E- EPS (ttm)-1.72 Insider Own0.10% Shs Outstand225.31M Perf Week0.24%
Market Cap19.69B Forward P/E- EPS next Y-0.54 Insider Trans- Shs Float204.62M Perf Month103.51%
Income-353.40M PEG- EPS next Q-0.25 Inst Own90.70% Short Float13.02% Perf Quarter140.55%
Sales20.40M P/S965.29 EPS this Y-120.60% Inst Trans15.38% Short Ratio6.57 Perf Half Y532.42%
Book/sh2.63 P/B32.41 EPS next Y51.40% ROA-51.30% Target Price73.56 Perf Year542.91%
Cash/sh4.22 P/C20.19 EPS next 5Y- ROE-131.90% 52W Range8.80 - 86.91 Perf YTD302.88%
Dividend- P/FCF- EPS past 5Y-29.10% ROI-118.00% 52W High-1.91% Beta2.55
Dividend %- Quick Ratio12.60 Sales past 5Y-44.60% Gross Margin91.80% 52W Low868.75% ATR2.65
Employees366 Current Ratio12.80 Sales Q/Q- Oper. Margin- RSI (14)86.64 Volatility0.45% 3.32%
OptionableYes Debt/Eq0.00 EPS Q/Q25.50% Profit Margin- Rel Volume0.84 Prev Close85.52
ShortableYes LT Debt/Eq0.00 EarningsAug 05 AMC Payout- Avg Volume4.05M Price85.25
Recom2.60 SMA2029.42% SMA5065.27% SMA200174.14% Volume3,418,747 Change-0.32%
May-05-20Initiated Barclays Overweight $40
Apr-24-20Upgrade Goldman Sell → Neutral $5 → $22
Apr-23-20Reiterated H.C. Wainwright Buy $34 → $60
Apr-06-20Upgrade Wells Fargo Equal Weight → Overweight $34
Apr-03-20Downgrade Goldman Buy → Sell $24 → $5
Dec-27-19Reiterated H.C. Wainwright Buy $26 → $31
Dec-20-19Initiated BofA/Merrill Buy $26
Aug-08-19Reiterated H.C. Wainwright Buy $28 → $26
Mar-27-19Initiated Berenberg Buy $40
Mar-04-19Initiated H.C. Wainwright Buy $28
Jan-18-19Downgrade Wells Fargo Outperform → Market Perform
Nov-08-18Resumed Jefferies Buy
Nov-05-18Initiated Morgan Stanley Overweight
Oct-19-18Initiated Piper Jaffray Overweight
Sep-17-18Initiated Goldman Buy $36
Jun-07-18Initiated B. Riley FBR, Inc. Buy $53
May-05-17Upgrade Wells Fargo Market Perform → Outperform
Oct-06-16Resumed Jefferies Buy
Jun-21-16Downgrade Wells Fargo Outperform → Market Perform
May-06-16Upgrade Jefferies Hold → Buy
Sep-26-20 06:25AM  
Sep-25-20 10:55PM  
10:35PM  
Sep-24-20 02:36PM  
07:23AM  
Sep-23-20 01:01PM  
Sep-22-20 06:45PM  
03:00PM  
Sep-21-20 03:10PM  
01:42PM  
10:13AM  
10:00AM  
Sep-20-20 09:45PM  
Sep-19-20 11:00AM  
10:30AM  
Sep-18-20 05:23PM  
04:16PM  
08:00AM  
Sep-17-20 02:50PM  
02:45PM  
Sep-16-20 01:29PM  
11:40AM  
09:47AM  
09:15AM  
08:41AM  
Sep-15-20 02:35PM  
01:51PM  
01:33PM  
12:35PM  
12:09PM  
07:25AM  
06:14AM  
Sep-14-20 04:38PM  
04:31PM  
04:25PM  
04:21PM  
04:17PM  
04:15PM  
04:00PM  
02:45PM  
12:48PM  
11:42AM  
11:26AM  
10:33AM  
10:28AM  
10:03AM  
10:03AM  
10:01AM  
09:28AM  
09:00AM  
08:42AM  
07:30AM  
01:27AM  
12:45AM  
Sep-13-20 10:41PM  
10:28PM  
10:00PM  
08:11PM  
06:17PM  
03:24PM  
03:00PM  
01:56AM  
Sep-12-20 06:22PM  
03:49PM  
03:28PM  
Sep-10-20 10:17AM  
Sep-09-20 07:00AM  
Sep-04-20 11:31AM  
Sep-02-20 08:00AM  
Aug-31-20 10:36PM  
Aug-20-20 07:20PM  
Aug-17-20 08:00AM  
Aug-05-20 06:35PM  
04:00PM  
Jul-29-20 03:31PM  
Jul-27-20 04:10PM  
02:23PM  
01:41PM  
08:00AM  
Jul-17-20 11:16AM  
Jul-15-20 01:15PM  
Jul-14-20 11:00AM  
Jul-13-20 04:00PM  
Jul-12-20 01:19PM  
Jul-09-20 03:55PM  
Jul-08-20 11:29AM  
Jul-07-20 11:30AM  
10:22AM  
08:17AM  
Jul-06-20 10:54AM  
10:36AM  
07:55AM  
06:49AM  
Jul-02-20 04:05PM  
Jun-29-20 04:25PM  
Jun-24-20 06:01PM  
Jun-19-20 11:30AM  
Jun-08-20 04:15PM  
Jun-05-20 05:33PM  
11:31AM  
Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. It also develops IMMU-140, a humanized antibody directed against an immune response target. Its other product candidates include products for the treatment of cancer and autoimmune diseases, including epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. The company has clinical collaboration with AstraZeneca, MedImmune, and Roche; collaboration agreement with The Bayer Group; clinical and preclinical collaborations with academic cancer institutions; and research collaboration with the Memorial Sloan Kettering Cancer Center. It also has a partnership agreement with the Samsung BioLogics Co., Ltd. to manufacture hRS7, an Immunomedics proprietary humanized antibody; and a collaboration and license agreement with pH Pharma Co. Ltd. for the development and commercialization of multiple novel antibody-drug conjugates in oncology. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Duncan Barbara GayleDirectorSep 14Option Exercise16.962,50042,40039,577Sep 15 04:30 PM
Duncan Barbara GayleDirectorAug 17Option Exercise16.9620,000339,20037,077Aug 20 04:15 PM
Duncan Barbara GayleDirectorAug 12Option Exercise12.9317,077220,80617,077Aug 14 04:33 PM
Avoro Capital Advisors LLCDirectorMay 01Buy28.501,750,00049,875,00026,250,000May 01 10:20 AM
Avoro Capital Advisors LLCDirectorDec 05Buy17.502,000,00035,000,00024,500,000Dec 09 04:05 PM
BALL BRYANChief Quality OfficerOct 03Buy14.185,00070,89710,000Oct 03 05:30 PM
Avoro Capital Advisors LLCDirectorOct 03Buy14.10500,0007,050,00022,500,000Oct 04 09:50 AM
Avoro Capital Advisors LLCDirectorOct 02Buy13.231,000,00013,230,00022,000,000Oct 04 09:50 AM